First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report.
clinical research/practice
crossmatch
desensitization
histocompatibility
immunosuppressant–other
immunosuppression/immune modulation
lung transplantation/pulmonology
panel reactive antibody (PRA)
rejection: antibody-mediated (ABMR)
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
27
06
2022
revised:
10
10
2022
accepted:
13
11
2022
pubmed:
26
1
2023
medline:
25
2
2023
entrez:
25
1
2023
Statut:
ppublish
Résumé
Lung transplant candidates who are highly sensitized against human leucocyte antigen present an ongoing challenge with regards to finding immunologically acceptable donors. Desensitization strategies aimed at reducing preformed donor-specific antibodies have a number of limitations. Imlifidase, an IgG-degrading enzyme derived from Streptococcus pyogenes, is a novel agent that has been used to convert positive crossmatches to negative in kidney transplant candidates, allowing transplantation to occur. We present the first case of imlifidase use for antibody depletion in a highly sensitized lung transplant candidate who went on to undergo a successful bilateral lung transplant.
Identifiants
pubmed: 36695676
pii: S1600-6135(22)29297-1
doi: 10.1016/j.ajt.2022.11.025
pii:
doi:
Substances chimiques
Antibodies
0
Immunosuppressive Agents
0
HLA Antigens
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
294-297Informations de copyright
Copyright © 2022 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.